Development of Continuous Glucose Monitoring System Cohort for Personalized Diabetes Prevention and Management Platform

Pusan National University Hospital130 enrolled

Overview

The purpose of this study is to collect a variety of clinical data and blood glucose changes using a continuous glucose monitoring device for high-risk diabetes patients (prediabetes) in order to develop a personalized diabetes prevention and management platform based on artificial intelligence model using mathematical analysis.

After being informed about the study and potential risks, all patients giving written informed consent wear a continuous glucose monitoring device ("iPro2" professional continuous glucose monitoring, MedtronicⓇ, California, USA) and smart band ("Fitbit Inspire HR", FitbitⓇ, California, USA) for 1 week. During this period, all patients are tested oral glucose tolerance test and take a standard diet (calorie calculated) at morning. The patient's data from this study is compared to a predicted values by mathematical analysis model for diabetes prevention.

Study Type

OBSERVATIONAL

Enrollment

130

Conditions

PreDiabetes Glucose Metabolism Disorders Diabetes Mellitus

Interventions

continuous glucose monitoring systemDEVICE

wearing continuous glucose monitoring device (iPro2 professional continuous glucose monitoring, MedtronicⓇ, California, USA)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Above 18 years old. * Prediabetes 1. Fasting plasma glucose : 100\~125mg/dL, fasting is defined as no caloric intake for at least 8 hours. OR 2. 2-hour plasma glucose during 75g oral glucose tolerance test : 140 \~ 199mg/dL OR 3. Glycated hemoglobin(HbA1c) : 5.7\~6.4% (39-47mmol/mol) Exclusion Criteria: * with a history of newly diagnosed and treated cancer within the last 5 years * with a history of hospitalization for active disease within the last 3 months * with a history of severe cardiovascular disease within the last 3 months * with a history of steroid treatment in the last 3 months * people who have had major surgery planned within the last 3 months or who have had surgery within 3 months * people who are pregnant or have been in the last 3 months after giving birth

Locations (1)

Pusan national university hospital

Busan, South Korea

Outcomes

Primary Outcomes

Number of Participants With Insulin Resistance

the prevalence of insulin resistance in participants was measured. Insulin resistance was calculated by HOMA-IR(homeostatic model assessment of insulin resistance), QUICKI (quantitative insulin sensitivity check index) and Matsuda index

Time frame: 1 week

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.